• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Japan Neuropsychiatric Disorders Treatment Market

    ID: MRFR/HC/43514-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    Japan Neuropsychiatric Disorders Treatment Market Research Report By Type (Degenerative Diseases, Neurotic Disorders, Psychosis, Others), By Application (Shock Treatment, Drug Treatment, Others) and By End User (Hospitals, Clinics, Research Centre’s, Others)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Japan Neuropsychiatric Disorders Treatment Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Japan Neuropsychiatric Disorders Treatment Market Summary

    The Japan Neuropsychiatric Disorders Treatment market is projected to grow significantly from 5.5 USD billion in 2024 to 16.5 USD billion by 2035.

    Key Market Trends & Highlights

    Japan Neuropsychiatric Disorders Treatment Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 10.5% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 16.5 USD billion, indicating robust growth potential.
    • In 2024, the market is valued at 5.5 USD billion, reflecting the current demand for neuropsychiatric treatments in Japan.
    • Growing adoption of innovative treatment methodologies due to increasing awareness of mental health issues is a major market driver.

    Market Size & Forecast

    2024 Market Size 5.5 (USD Billion)
    2035 Market Size 16.5 (USD Billion)
    CAGR (2025-2035) 10.5%

    Major Players

    H. Lundbeck A/S, Roche, Daiichi Sankyo, Otsuka Pharmaceutical, Johnson and Johnson, Novartis, Sumitomo Dainippon Pharma, Astellas Pharma, Mitsubishi Tanabe Pharma, Pfizer, Santen Pharmaceutical, AbbVie, Eisai, Kyowa Hakko Kirin, Takeda Pharmaceutical

    Japan Neuropsychiatric Disorders Treatment Market Trends

    The Japan Neuropsychiatric Disorders Treatment Market is showing significant changes because of the growing prevalence of mental health disorders. There is rising awareness of neuropsychiatric disorders and mental health problems due to government policies, which have made treatment facilities readily available.

    The shift towards integrating mental healthcare into other core health services demonstrates a move towards comprehensive treatment methodology. This facilitates holistic approaches and provides continuous care for disorders like depressionanxiety, and schizophrenia.

    Other important factors of the market include the elderly population in Japan who suffers from neuropsychiatric disorders and who need advanced treatment options.

    In addition, more and more people are willing to self-identify and get a diagnosis, which propels the need for new therapies and medicines. This reduces sociocultural stigma around mental illness.

    There is great potential for improved patient participation and access to care, especially in rural areas, where telemedicine and digital therapeutics can be used. New changes indicate that more pharmaceutical companies are working with information technology companies to design better forms of treatment.

    This partnership's goal is to ease the burden of patients taking their medications and improve outcomes of medical treatment. Also, the amount of spending that the Japanese government directs toward mental health policy reform as well as research funding captures associated growth potential.

    In general, the market for the treatment of neuropsychiatric disorders in Japan is set to shift for the better. This will happen with further strides in the provision of technology-based services and the development of community-centered care approaches.

    Market Segment Insights

    Japan Neuropsychiatric Disorders Treatment Market Segment Insights

    Japan Neuropsychiatric Disorders Treatment Market Segment Insights

    Neuropsychiatric Disorders Treatment Market Type Insights

    Neuropsychiatric Disorders Treatment Market Type Insights

    The Japan Neuropsychiatric Disorders Treatment Market is increasingly structured around various types of disorders, leading to significant advancements in treatment and care. The classification includes degenerative diseases, neurotic disorders, psychosis, and others, each presenting unique characteristics and treatment approaches. Degenerative diseases, such as Alzheimer's and Parkinson's, are particularly crucial due to the aging population in Japan, which faces a growing prevalence of cognitive impairments and neurological decline.

    Neurotic disorders encompass a range of anxiety and mood disorders that significantly impact daily functioning and quality of life.Treatments in this area continue to evolve, reflecting societal changes and increased awareness of mental health issues. Psychosis, which includes conditions like schizophrenia, calls for an urgent need for effective therapeutic options as societal stigma often hinders diagnosis and access to care, making education and innovation key priorities. The 'others' category captures various other neuropsychiatric conditions that may not fall within conventional classifications but still significantly affect mental health and well-being.

    Collectively, this segmentation highlights the diversified landscape of neuropsychiatric disorders, where tailored treatment options address the specific needs of Japan’s population, fostering an environment of support and improved mental health initiatives.The understanding of these segments is critical in shaping healthcare policies and resource allocation in Japan, as they inform both market growth dynamics and the rising demand for comprehensive mental health services.

    Neuropsychiatric Disorders Treatment Market Application Insights

    Neuropsychiatric Disorders Treatment Market Application Insights

    The Japan Neuropsychiatric Disorders Treatment Market is characterized by diverse applications that play vital roles in addressing various mental health challenges. Among these, Shock Treatment has garnered attention for its effectiveness in severe cases, offering a rapid intervention that can result in immediate symptom relief for patients. Drug Treatment remains a cornerstone of this market, as advancements in pharmaceuticals continue to enhance treatment efficacy and patient outcomes for conditions ranging from depression to anxiety disorders.The 'Others' category captures emerging therapies and holistic approaches, catering to a growing demand for personalized and integrative treatment options in the Japanese healthcare system.

    Japan's commitment to mental health care innovation supports the integration of these applications, promoting greater accessibility and awareness of neuropsychiatric conditions. The Japan Neuropsychiatric Disorders Treatment Market revenue reflects these developments, as the nation increasingly prioritizes mental health within public health initiatives. Furthermore, behavioral health trends, such as destigmatization and increased diagnostics, are paving the way for improved treatment modalities and making substantial contributions to market growth.

    Neuropsychiatric Disorders Treatment Market End User Insights

    Neuropsychiatric Disorders Treatment Market End User Insights

    The Japan Neuropsychiatric Disorders Treatment Market is significantly influenced by its End User segmentation, which encompasses various healthcare facilities, each playing a vital role in the treatment landscape. Hospitals are a leading provider of neuropsychiatric care, equipped with the resources for comprehensive patient management and advanced treatments. Clinics serve as accessible points for outpatient care, focusing on early intervention and chronic management of neuropsychiatric disorders.

    Research centres are pivotal in driving innovation and clinical trials, contributing to the development of new therapies and treatment protocols.Additionally, other healthcare settings, such as community health organizations, complement these services by promoting awareness and providing support for patients and families. With Japan's aging population and increasing prevalence of neuropsychiatric conditions, these diverse End Users are crucial for addressing the growing demand for effective treatments and improving overall patient outcomes.

    The coordinated efforts of hospitals, clinics, and research centres enhance the Japan Neuropsychiatric Disorders Treatment Market, reflecting the need for a multifaceted approach in tackling mental health challenges across the country.

    Get more detailed insights about Japan Neuropsychiatric Disorders Treatment Market Research Report - Forecast to 2035

    Key Players and Competitive Insights

    The Japan Neuropsychiatric Disorders Treatment Market is characterized by a high level of competition among key players seeking to address the growing incidence of neuropsychiatric conditions such as depression, schizophrenia, and anxiety disorders. With an increasing awareness of mental health issues and the rising demand for effective treatment options, the market has attracted both established pharmaceutical companies and emerging biotechnological firms. As the Japanese population ages and the need for new therapies rises, companies are investing significantly in research and development to innovate and expand their product offerings.

    Regulatory challenges, pricing pressures, and the evolving landscape of treatment paradigms further define this competitive environment, compelling companies to differentiate themselves through unique product strategies, enhanced efficacy, and improved patient outcomes.H. Lundbeck A/S has established a significant presence in the Japan Neuropsychiatric Disorders Treatment Market, focusing on developing and marketing treatments for various neuropsychiatric disorders. The company is recognized for its commitment to research and innovation in the field, particularly in the development of therapies for depression and schizophrenia. H.

    Lundbeck A/S's strengths lie in its strong pipeline of drugs, robust clinical development programs, and partnerships with local stakeholders that facilitate market access and customer engagement. Their expertise in neuropharmacology positions them favorably in a competitive landscape, enabling them to effectively address unmet medical needs within Japan and deliver targeted treatments that align with the country’s healthcare standards.Roche has made inroads into the Japan Neuropsychiatric Disorders Treatment Market by focusing on personalized medicine and integrating its broad portfolio of pharmaceuticals with diagnostic tests.

    Renowned for its innovative anti-depressants and treatments for schizophrenia, Roche has positioned itself strategically by emphasizing the importance of tailored therapies to enhance treatment efficacy. The company benefits from a well-established market presence and has been involved in several strategic partnerships and acquisitions that have bolstered its capabilities to introduce advanced products in Japan. Roche’s strengths include its extensive research and development infrastructure and deep understanding of the Japanese healthcare landscape, which allow for better anticipation of market needs.

    Additionally, Roche’s collaborative efforts with local healthcare providers and stakeholders contribute to a diverse approach in tackling neuropsychiatric disorders, ultimately increasing accessibility and improving patient outcomes in Japan.

    Key Companies in the Japan Neuropsychiatric Disorders Treatment Market market include

    Industry Developments

    Significant developments have occurred in the Japan Neuropsychiatric Disorders Treatment Market in recent months. In October 2023, Daiichi Sankyo announced the successful launch of a new treatment for obsessive-compulsive disorder, demonstrating its commitment to expanding therapeutic options. Meanwhile, Otsuka Pharmaceutical reported positive results from a phase III trial for a novel antidepressant, anticipated to significantly enhance patient outcomes. The merger landscape remains active, with Astellas Pharma's acquisition of a small biotech specializing in neurodegenerative disorders completed in September 2023, signaling a strategy to broaden its portfolio.

    Concurrently, Mitsubishi Tanabe Pharma is expected to unveil new insights on its schizophrenia treatment at an upcoming medical forum, emphasizing its innovative research initiatives. Additionally, the overall market valuation for companies like Takeda Pharmaceutical and Novartis in the neuropsychiatric segment has seen growth driven by increased demand for mental health treatments amid rising societal awareness in Japan. Studies indicate that the Japanese government is enhancing its focus on mental health resources, which significantly influences ongoing developments in this sector. The market continues to be characterized by rapid advancements and a collaborative push towards improved mental health solutions for the population.

    Market Segmentation

    Outlook

    • Hospitals
    • Clinics
    • Research Centre’s
    • Others

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 4.94(USD Billion)
    MARKET SIZE 2024 5.5(USD Billion)
    MARKET SIZE 2035 16.5(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 10.503% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED H. Lundbeck A/S, Roche, Daiichi Sankyo, Otsuka Pharmaceutical, Johnson and Johnson, Novartis, Sumitomo Dainippon Pharma, Astellas Pharma, Mitsubishi Tanabe Pharma, Pfizer, Santen Pharmaceutical, AbbVie, Eisai, Kyowa Hakko Kirin, Takeda Pharmaceutical
    SEGMENTS COVERED Type, Application, End User
    KEY MARKET OPPORTUNITIES Aging population requiring mental health care, Advancements in telepsychiatry services, Increased funding for research innovations, Growing awareness of mental health issues, Expanding access to personalized treatment options
    KEY MARKET DYNAMICS Aging population increase, Rising prevalence of mental disorders, Advanced treatment technologies, Growing awareness and destigmatization, Government support and initiatives
    COUNTRIES COVERED Japan

    FAQs

    What is the expected market value of the Japan Neuropsychiatric Disorders Treatment Market in 2024?

    The Japan Neuropsychiatric Disorders Treatment Market is expected to be valued at 5.5 USD Billion in 2024.

    What will the market value be in 2035?

    By 2035, the market value is projected to reach 16.5 USD Billion.

    What is the expected compound annual growth rate (CAGR) for the market from 2025 to 2035?

    The expected CAGR for the Japan Neuropsychiatric Disorders Treatment Market from 2025 to 2035 is 10.503%.

    Which type of neuropsychiatric disorders holds the largest market share in 2024?

    Degenerative Diseases is projected to hold the largest market share valued at 1.5 USD Billion in 2024.

    What is the growth forecast for Psychosis in the market by 2035?

    The Psychosis segment is expected to grow to 3.0 USD Billion by 2035.

    Who are the major players in the Japan Neuropsychiatric Disorders Treatment Market?

    Key players include H. Lundbeck A/S, Roche, Daiichi Sankyo, and Otsuka Pharmaceutical among others.

    What is the expected market value for Neurotic Disorders in 2035?

    The expected market value for Neurotic Disorders is projected to be 3.6 USD Billion in 2035.

    How much is the Others segment expected to be valued at in 2024?

    The Others segment is expected to be valued at 1.8 USD Billion in 2024.

    What challenges could impact the Japan Neuropsychiatric Disorders Treatment Market?

    Challenges include regulatory hurdles and competition among established players.

    What are the growth drivers for the Japan Neuropsychiatric Disorders Treatment Market?

    Growth drivers include increasing awareness of mental health and advancements in treatment options.

    Japan Neuropsychiatric Disorders Treatment Market Research Report - Forecast to 2035 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Stories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study
    Chemicals and Materials